NEW
YORK, July 6, 2023 /PRNewswire/ -- The Gross Law
Firm issues the following notice to shareholders of Biomea
Fusion, Inc.:
On June 23, 2023, Biomea Fusion
presented data for its Type 2 diabetes drug candidate BMF-219 at a
meeting of the American Diabetes Association. In response to the
presentation, market analysts downgraded Biomea Fusion and its
stock price fell $6.25 per share,
from $30.67 per share on June 23, 2023 to close at $24.42 per share on June
26, 2023.
Due to the forgoing, The Gross Law Firm is investigating
potential securities fraud claims on
behalf of certain Biomea Fusion investors. If you incurred a loss
on your BMEA investment, please contact us using the link below to
discuss your rights.
https://securitiesclasslaw.com/securities/biomea-fusion-loss-submission-form/?id=41699&from=4
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business
practices. The Gross Law Firm is committed to ensuring that
companies adhere to responsible business practices and engage in
good corporate citizenship. The firm seeks recovery on behalf of
investors who incurred losses when false and/or misleading
statements or the omission of material information by a company
lead to artificial inflation of the company's stock. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/investigation-alert-the-gross-law-firm-notifies-shareholders-of-biomea-fusion-inc-of-an-investigation-and-potential-class-action-lawsuit--nasdaq-bmea-301870560.html
SOURCE The Gross Law Firm